TÜRK POPÜLASYONUNDA APE1 ASP148GLU GEN POLİMORFİZMİNİN MESANE KANSERİ İLE İLİŞKİSİ BULUNMAMAKTADIR

Abstract

Amaç: Çalışmamızda, APE1 (Asp148Glu) gen polimorfizmi ile mesane kanseri oluşumu ve gelişimi arasındaki ilişkiyi araştırmayı amaçladık. Ayrıca, mesane kanserinde sigara kullanımı ile APE 1 gen polimorfizmi arasındaki ilişkiyi değerlendirmeyi planladık. Gereç ve yöntem: Çalışmamızda histopatolojik ve klinik açıdan mesane kanseri tanısı konan hastalar (n=120) ve sağlıklı normal kişiler (n=136) yer aldı. Çalışma grubundaki kişilerden elde edilen DNA’lardan Apürinik/ Aprimidinik Endonükleaz 1 (APE1) gen polimorfizmi için polimeraz zincir reaksiyonu (PZR), sınırlayıcı enzim parça uzunluğu polimorfizmi (RFLP) teknikleri kullanıldı. Bulgular: APE1 gen polimorfizminde genotip ve allel sıklığı incelendiğinde mesane kanseri ve kontrol grubu arasında anlamlı farklılık bulunmamaktadır. İlaveten, yüksek grade, ileri evre ve sigara kullanımı bakımından da incelendiğinde anlamlı bir faklılık bulunmamaktadır. Sonuç: APE 1 gen polimorfizminin mesane kanseri oluşumunda ve gelişiminde bir risk içermediğini ayrıca, sigara kullanımının APE Asp148Glu gen polimorfizminde etkili olmadığını ileri sürebiliriz.

Keywords

• APE1
• polimorfizm
• baz kesip çıkarma onarımı
• mesane kanseri

GENETIC POLYMORPHISM OF APE1 ASP148GLU IS NOT ASSOCIATED WITH BLADDER CANCER RISK IN A TURKISH POPULATION

Abstract

Objective: The purpose of this investigative research was to investigatethe potential impact of a single nucleotide polymorphism (Asp148Glu) within the APE1 gene on the development of bladder cancer (BCa) andspread, and to investigate the interaction of this polymorphism withcigarette smoking in BCa patients. Materials and Methods: In a study of 256 participants, consisting of 136 healthy individuals and 120 patients with BCa, the APE1 Asp148Glu polymorphism was evaluated using “polymerase chain reaction restrictionfragment length polymorphism” analysis. Results: There were no noteworthy difference variations observed in genotype distribution between the group of individuals with BCa and the control group with regards to the APE1 gene polymorphism. Furthermore, the APE1 gene polymorphism exhibited no correlation with the clinicopathological characteristics or smoking habits of individuals with BCa. Conclusion: Based on our findings, it appears that the APE1 gene polymorphism, which plays a role in the BER pathway, does not appear to be a contributing factor in susceptibility to BCa in the Turkish population. In addition, the smoking habit may not modify BCa risk with respect to genetic variations in the APE1 gene.

Keywords

• APE1
• polymorphism
• base excision repair
• bladder cancer

References

1. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel) 2020;8(1):15.
2. Wong MC, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng ACF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep 2018;8:1129.
3. Antoni SFJ, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 2017;71(1):96-108.
4. Shah F, Logsdon D, Messmann RA, Fehrenbacher JC, Fishel ML, Kelley MR. Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol 2017;1:19.
5. Choi S, Shin JH, Lee YR, Joo HK, Song KH, Na YG, et al. Urinary APE1/Ref-1: A potential bladder cancer biomarker. Dis Markers 2016;2016:7276502.
6. Fishel ML, Xia H, McGeown J, McIlwain DW, Elbanna M, Craft AA, et al. Antitumor activity and mechanistic characterization of APE1/Ref-1 inhibitors in bladder cancer. Mol Cancer Ther 2019;18(11):1947-60.
7. Mir SM, Aliarab A, Goodarzi G, Shirzad M, Jafari SM, Qujeq D, et al. Melatonin: A smart molecule in the DNA repair system. Cell Biochem Func 2021;40(1):4-16.
8. Gangwar R, Ahirwar D, Mandhani A, Mittal RD. Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in North India. Urology 2009;73(3):675-80.

9. Benhamou S, Sarasin A. Variability in nucleotide excision repair and cancer risk: a review. Mutat Res 2000:462(2-3):149-58.
10. Huang HI, Chen CH, Wang SH, Wang LH, Lin YC. Effects of APE1 Asp148Glu polymorphisms on OPMD malignant transformation, and on susceptibility to and overall survival of oral cancer in Taiwan. Head Neck 2019:41(6):1557-64.
11. McIlwain DW, Fishel ML, Boos A, Kelley MR, Jerde TJ. APE1/ Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells. Oncotarget 2018;9(13):10962-77.
12. Zhang S, Wang LA, Li Z, Peng Y, Cun YP, et al. APE1 polymorphisms are associated with colorectal cancer susceptibility in Chinese Hans. World J Gastroenterol 2014;20(26):8700-8.
13. Qing Li, Jian-Min Wang, Yu Peng, Shi-Heng Zhang, Tao Ren, Hao Luo, et al. Association of DNA Base-excision Repair XRCC1, OGG1 and APE1 gene polymorphisms with nasopharyngeal carcinoma susceptibility in a Chinese population. Asian Pac J Cancer Prev 2013;14(9):5145-51.
14. Narter KF. Analysis of XRCC3, hOGG1, XPD, XRCC1, XPG and APE1 Gene Polymorphisms in patients with bladder cancer. Istanbul University Institute of Health Sciences, PhD Thesis of Department of Molecular Medicine, 2008.
15. Karahalil B, Aygün Kocabaş N, Özçelik T. DNA repair gene polymorphisms and bladder cancer susceptibility in a Turkish population. Anticancer Res 2006;26(6C):4955-8.
16. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, Miller AB. Risk of bladder cancer by source and type of tobacco exposure: A case-control study. Int J Cancer 1989;44(4):622-8.
17. Kucukgergin C, Sanli O, Amasyalı AS, Tefik T, Seckin S. Genetic variants of MnSOD and GPX1 and susceptibility to bladder cancer in a Turkish population. Med Oncol 2012;29(3):1928-34.
18. Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, et al. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int J Cancer 2014;135(11):2687-97.
19. Ahirwar DK, Marthani A, Mittal RD. IL-8 -251 T>A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a Northern Indian cohort. Arch Med Res 2010;41(2):97-103.
20. Terry PD, Umbach DM, Taylor JA. APE1 genotype and risk of bladder cancer: Evidence for effect modification by smoking. Int J Cancer 2006;118(12):3170-3.
21. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, Wijkström H, Larsson P, Kumar R, Hemminki K. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004;25(5):729-34.
22. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001;22(6):917-22.
23. Gu D, Wang M, Zhang Z, Chen J. The DNA repair gene APE1 T1349G polymorphism and cancer risk: a meta-analysis of 27 case-control studies. Mutagenesis 2009;24(6):507-12.
24. Canbay E, Agachan B, Gulluoglu M, Isbir T, Balik E, Yamaner S, et al. Possible associations of APE1 polymorphism with susceptibility and HOGG1 polymorphism with prognosis in gastric cancer. Anticancer Res 2010;30(4):1359-64.
25. Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL. Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control 2010;21(2):289-300.
26. Wang M, Qin C, Zhu J, Yuan L, Fu G, Zhang Z, Yin C. Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer. DNA Cell Biol 2010;29(6):303-11.
27. Dhillon VS, Yeoh E, Fenech M. DNA repair gene polymorphisms and prostate cancer risk in South Australia results of a pilot study. Urol Oncol 2011;29(6):641-6.
28. Chuan Liu, Qinghua Yin, Lian Li, Ying-zhi, Zhuang Xuyu Zu, Yajie Wang. APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis. Mol Biol Rep 2013;40(1):171-6.